Atara Biotherapeutics (Atara Biotherapeutics) Interest Expense : $-5.29 Mil (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Atara Biotherapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Atara Biotherapeutics's interest expense for the three months ended in Dec. 2023 was $ -1.18 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.29 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Atara Biotherapeutics's Operating Income for the three months ended in Dec. 2023 was $ -59.96 Mil. Atara Biotherapeutics's Interest Expense for the three months ended in Dec. 2023 was $ -1.18 Mil. Atara Biotherapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Atara Biotherapeutics Interest Expense Historical Data

The historical data trend for Atara Biotherapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics Interest Expense Chart

Atara Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.37

-5.29

Atara Biotherapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.12	-1.34	-1.38	-1.40	-1.18

Atara Biotherapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.29 Mil.

Atara Biotherapeutics (NAS:ATRA) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Atara Biotherapeutics's Interest Expense for the three months ended in Dec. 2023 was $-1.18 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-59.96 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $45.69 Mil.

Atara Biotherapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Atara Biotherapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Atara Biotherapeutics (Atara Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (NAS:ATRA) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

AT2:Germany AT2:Germany

Address

2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, USA, 91320

Website

https://www.atarabio.com

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Executives

Jill Henrich	officer: EVP, Global Head RA & Quality	2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Pascal Touchon	director, officer: President and CEO	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD SUITE 900, SOUTH SAN FRANCISCO CA 94080
Amar Murugan	officer: SVP, GC & Secretary	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD,SUITE 900, SOUTH SAN FRANCISCO CA 94080
Eric J Hyllengren	officer: SVP, CFO	2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Anhco Nguyen	officer: EVP, Chief Sci. & Tech Officer	2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Manher Joshi	officer: EVP, Chief Medical Officer	2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Carol Giltner Gallagher	director	C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Eric Dobmeier	director	C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
William K Heiden	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Charlene A. Banard	officer: EVP, Chief Technical Officer	C/O APPLIED MOLECULAR TRANSPORT INC., 450 EAST JAMIE COURT, SOUTH SAN FRANCISCO CA 94080
Jakob Dupont	officer: EVP, Head of R&D	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Utpal Koppikar	officer: Chief Financial Officer	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO CA 94080
Ameet Mallik	director	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Kristin Yarema	officer: Chief Commercial Officer	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO CA 94080
Joe Newell	officer: Chief Tech. Operations Officer	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO CA 94080